Introduction {#sec1-1}
============

Vascular Endothelial Growth Factor has been identified as an endothelial cell-specific mitogen and angiogenic stimulator *in vivo*. Multiple biologically active forms of VEGF-A are generated by both alternative mRNA splicing and posttranslational modification (proteolytic cleavage), and two of these forms (VEGF165 and VEGF121) have been detected in choroidal neovascular lesions. Anti-VEGFs (namely Ranibizumab, Bevacizumab, Pegabtinib) are stable small RNA-like molecules that bind to the 165-kDa isoform of human VEGF and inactivate it, thereby reducing the retinal and choroidal angiogenesis and halting the increase in vascular permeability.\[[@ref1]\]

Intracameral injections of bevacizumab for treatment of neovascular glaucoma can cause corneal endothelial cell loss as determined by specular microscopy, although the endothelial cell loss is less as compared to that occurring after cataract surgeries or glaucoma surgeries.\[[@ref2]\] Although the pharmacokinetic profile of ranibizumab after intravitreal injection in human eyes has not been determined definitively, ranibizumab has been detected in the aqueous humor after intravitreal standard injections in animal models.\[[@ref1][@ref2]\] Moreover, VEGF and its receptors were expressed in the corneal endothelium.\[[@ref3][@ref4][@ref5][@ref6]\] Therefore, ranibizumab in the aqueous humor after intravitreal injections may affect the function of VEGF in the corneal endothelium.

There has been a paucity of studies to elucidate the possible endothelial toxicity of anti-VEGF molecules in the Indian population, and it is this void that we have attempted to fill in this study.

Materials and Methods {#sec1-2}
=====================

The study was conducted prospectively over a time period of 18 months. 102 eyes requiring intra-vitreal anti-VEGF drugs for macular oedema, age-related macular degeneration or retinal vein occlusion were selected (as per selection criteria) for evaluation and a comparative follow-up. Sample size was calculated in order to achieve a power of study 80% at *P* \< 0.05 based on the number of patents attending the speciality retina clinic of our tertiary health care centre (i.e. keeping in mind the prevalence of the etiologies in question). Institutional Review Board (IRB)/Ethics Committee approval was obtained.

Patients aged 40-80 years who were willing to come for regular follow-up, were included in the study if they demonstrated focal or diffuse macular edema on Optical Coherence Tomography (OCT) due to age-related macular degeneration or retinal venous occlusion requiring intravitreal anti-VEGF injection.

Patients were excluded if they had pre-existing glaucoma or glaucoma shunt surgery, aphakic and vitrectomised patients, corneal scarring or preexisting corneal disease like Fuchs endothelial dystrophy, that could lower endothelial cell count, contact lens users, any ocular trauma that disrupts the structural integrity of cornea, previous recipients of anti-VEGF injection and uncooperative patients who were unable to perform specular microscopy.

At first patient visit, a detailed medical history was obtained. Furthermore, the following examinations were performed:

Snellen\'s best corrected visual acuity (BCVA)Intraocular pressure (IOP) was measured with non contact tonometry (NCT)Slit lamp examination of anterior segment.Fundus examinationSpecular microscopy (Konan Noncon Robo NSP-7700) was done to look for endothelial cell count and Central corneal thickness. An average of 3 readings were taken. Patients were asked always to look at the central fixation target and the auto-alignment function was used. All corneal endothelial cells which were clearly visible on the picture were marked manually. Endothelial cell density (ECD) were calculated by the instruments' built-in software after marking 20 discrete points.

At second visit, injection ranibizumab 0.5 mg/0.05 ml was administered through the pars plana into the vitreous cavity using a 30G needle at a limbal distance of 3.5 mm in pseudophakics and 4 mm in phakics.

Post-operatively, the patient was given Tablet acetazolamide 250 mg 2 tablets stat, E/D moxifloxacin 0.5% QID × 7 days and E/D bromfenac 0.09% BD × 7 days.

3 more visits were performed at 1 day, 7 days and 1 month post-operatively, to quantify endothelial cell density and central corneal thickness by specular microscopy.

Statistical analysis {#sec2-1}
--------------------

Patients were divided into 2 groups for the purpose of evaluation:

Group 1: Phakic patients.

Group 2: Pseudophakic patients.

Categorical variables were presented in number and percentage (%) and continuous variables was presented as mean ± SD and median. Normality of data was tested by Kolmogorov-Smirnov test. If the normality was rejected, then non-parametric test was used with the power of the study being 80% such that *P* \< 0.05 being considered statistically significant.

The statistical tests were applied as follows:

Quantitative variables were compared using Wilcoxon ranked sum test to compare pre with post test results and independent T test/Mann whitney Test (for non parametric data) to compare two groups.Qualitative variables were compared using Chi-Square test/Fisher\'s exact test.

A *P* value of \< 0.05 was considered statistically significant.

The data was entered in MS EXCEL spreadsheet and analysis was done using Statistical Package for Social Sciences (SPSS) version 21.0.

Results {#sec1-3}
=======

Patients were divided into 2 groups for the purpose of evaluation:

Group 1: Phakic patients.

Group 2: Pseudophakic patients.

Since both groups were age and sex matched, there was not much difference between them with respect to the indications for intravitreal injections. Ref. [Table 1](#T1){ref-type="table"}.

###### 

Baseline parameters

  VARIABLES           GROUP 1 PSEUDOPHAKIC   GROUP 2 PHAKIC   *P*
  ------------------- ---------------------- ---------------- -------
  MEAN AGE            62.35±6.55             60.86±6.99       0.269
  PRE INJECTION CCT   503.9±19.1             506.5±22.6       0.632
  PRE INJECTION ECD   2287.1±303.4           2314.7±218.1     0.864
  INDICATION FOR                                              
  INTRAVITREAL                                                
  INJECTION                                                   
  1\. ARMD            29                     31               
  2\. VASCULAR        21                     19               
  OCCLUSIONS                                                  

2 patients were lost to follow up due to death, and so the final statistical analysis was carried out on 100 patients.

There was no significant difference between the two groups in terms of mean age (*P* = 0.269), pre injection central corneal thickness (CCT) (*P* = 0.632), pre injection endothelial cell density (ECD) (*P* = 0.864), pre injection coefficient of variation (CV) (*P* = 0.350). Ref. [Table 1](#T1){ref-type="table"}.

The mean CCT value in phakic group was 506.53 ± 22.61, 505.96 ± 20.12, 505.92 ± 20.3 and 505.69 ± 21.47. The mean CCT values in phakics decreased by 0.07% ± 2.08%, 0.07% ± 2.60% and 0.12% ± 2.60% day 1, 7 and 30, respectively. This change in mean CCT value was not statistically significant (*P* \> 0.05). Ref. [Table 2](#T2){ref-type="table"}.

###### 

Comparision of pre injection and post injection (day 1, 7 & 30) CCT (um) between pseudophakics and phakic group

  PARAMETER          GROUP 2 PSEUDOPHAKIC        GROUP 1 PHAKIC              *P* (intergroup)
  ------------------ --------------------------- --------------------------- ------------------
  PREINJECTION CCT   503.9±19.1                  506.5±22.6 (−0.07%±2.08%)   0.632
  CCT day 1          502.0±19.9 (−0.34%±3.03%)   505.9±20.1 (−0.07%±2.60%)   0.328
  CCT day 7          501.9±20.3 (−0.36%±3.46%)   505.9±20.3                  0.298
  CCT day 30         501.7±21.5 (−0.40%±3.65%)   505.6±21.4 (−0.12%±2.60%)   0.416

The mean CCT value in pseudophakic group was 502.08 ± 19.91, 501.9 ± 20.31, and 501.72 ± 21.55 on day 1, 7 and 30, respectively. The mean CCT values decreased by 0.34% ± 3.03%, 0.36% ± 3.46% and 0.40% ± 3.65% on day 1, 7 and 30, respectively. This change in mean CCT was not statistically significant (*P* \> 0.05). Ref. [Table 2](#T2){ref-type="table"}.

There was also no significant difference between the phakic and pseudophakic patients in terms of change in mean CCT values (*P* \> 0.05). Ref. [Table 2](#T2){ref-type="table"}.

The mean value of ECD in phakic eyes on day 1, 7, and 30 were 2314.51 ± 212.08, 2313.92 ± 212.7 and 2313.63 ± 216.86 cells/mm^2^, respectively. It reduced by 0.02% ± 1.39%, 0.00% ± 1.54% and 0.04% ± 1.41%, respectively. The decrease however was not statistically significant (*P* \> 0.05). Ref. [Table 3](#T3){ref-type="table"}.

###### 

Comparison of pre injection and post injection (day 1, 7 & 30) ECD (cells/mm^3^) between pseudophakics and phakic group

  PARAMETER           GROUP 1 PSEUDOPHAKIC          GROUP 2 PHAKIC                *P*
  ------------------- ----------------------------- ----------------------------- -------
  Pre injection ECD   2287.1±303.4                  2314.7±218.1                  0.864
  ECD day 1           2284.2±299.8 (−0.06%±2.98%)   2314.5±212.0 (−0.02%±1.39%)   0.899
  ECD day 7           2281.3±289.4 (−0.08%±3.66%)   2313.9±212.7 (−0.00%±1.54%)   0.925
  ECD day 30          2284.0±312.6 (−0.16%±3.79%)   2313.6±216.8 (−0.04%±1.41%)   0.606

The mean value of ECD in pseudophakic eyes on day 1, 7, and 30 were 2284.24 ± 299.86, 2281.39 ± 289.46 and 2284.06 ± 312.65 cells/mm^2^, respectively. It decreased by 0.06% ± 2.98%, 0.08% ± 3.66% and 0.16% ± 3.79%, respectively, on day 1, 7 and 30, respectively. The decrease however was not statistically significant (*P* \> 0.05). Ref. [Table 3](#T3){ref-type="table"}.

There was no significant difference between phakic and pseudophakic eyes in terms of ECD (*P* \> 0.05). Ref. [Table 3](#T3){ref-type="table"}.

Discussion {#sec1-4}
==========

Although the pharmacokinetic profile of ranibizumab after intravitreal injection in human eyes has not been determined definitively, ranibizumab has been detected in the aqueous humor after intravitreal standard injections in animal models.\[[@ref1][@ref2]\] In a rabbit study, ranibizumab was present in the aqueous humor of eyes after a 0.5-mg intravitreal injection of ranibizumab but was not detected in the serum or the fellow untreated eyes. Concentrations exceeding 0.1 mg/mL of ranibizumab were maintained in the ocular compartments for 29 days.

Previously, many studies have shown that VEGF and its receptors are expressed in cornea. Gan *et al.*\[[@ref7]\] in 2004 found out that VEGF is expressed in rabbit eyes in corneal epithelium, and endothelium but not in corneal stroma. They also observed that VEGFR-2 was present in the corneal epithelial and endothelial cells but absent in keratinocytes. Phillip *et al.*\[[@ref8]\] also found out that VEGF and VEGFR are present in corneal epithelium and endothelium but not on keratinocytes, and that their expression was increased in patients with inflamed and injured cornea, thereby indicating that VEGF may be involved in neovascularisation of injured and inflamed human corneas.

Yoeruek *et al.*\[[@ref9]\] in 2007 did an *in vitro* study and reported that all human corneal cell lines were immunopositive for VEGF, VEGFR-1 and VEGFR-2. It is therefore reasonable to consider that ranibizumab may have cytotoxic effects on corneal endothelium.

J. Benitz herreros *et al.*\[[@ref10]\] in 2010 conducted the morphometric analysis of corneal endothelium after 0.5 mg intravitreal ranibizumab injection in AMD patients using corneal specular microscopy on American population. In their study, there was no significant difference in the corneal endothelial cell density and central corneal thickness at 6 months. Consuelo Perez-Rico *et al.*\[[@ref11]\] conducted a prospective observational case series study in 2010 on effect of intravitreal ranibizumab on corneal endothelium in patients of age-related macular degeneration, which showed that there was no significant effect on endothelial cell count, coefficient of variation, % of hexagonal cells and central corneal thickness after a follow-up of 6 months. Chun-Chi Chiang *et al.*\[[@ref12]\] in 2008 and Tseng JJ *et al.*\[[@ref13]\] in 2012 conducted a six monthly follow-up study to determine the effect of 2.5 mg intravitreal bevacizumab on central corneal thickness. This study showed that there was no significant difference in central corneal thickness before and after injection. Our study results indicated that intravitreal injection of 0.5 mg of anti-VEGF in patients with AMD or macular oedema secondary to RVO did not cause a significant change in central corneal thickness, endothelial cell density, coefficient of variation as compared to the preinjection values, as measured by specular microscopy over 1 month of follow-up, which is in accordance with the above review of previous studies.

We would now like to talk about the strengths of the study. Our study strongly supports that a single intravitreal injection of anti-VEGF (0.5 mg ranibizumab) does not seem to cause significant changes in corneal endothelium and intraocular pressure. Also, unlike many other similar studies with smaller sample sizes, the statistical significance and validity of this study is corroborated by the fact that we had a sample size of over 100 patients.

However, there are a few weaknesses to the study. Firstly, most patients end up requiring more than one intravitreal injection to attain anatomical and functional integrity of the retina. Hence, this study applies to that section of patients requiring a single dose intravitreal anti-VEGF injection and the effect of multiple doses of intravitreal anti-VEGF injections need to be investigated. Secondly, even though we could conclude that a single intravitreal injection may not harm the cornea adversely, it cannot be extrapolated to patients with mildly or partially decompensated corneas wherein even a single injection might affect the endothelium adversely. Thirdly, the results of this study are confined to one month of follow-up. The long term effects of intravitreal anti-VEGF may still require further evaluation. And lastly, this study cannot be extrapolated to aphakic vitrectomised patients wherein the intravitreal anti-VEGF is amenable to direct access to the anterior chamber.

General practitioners and family physicians are generally the first point of contact for healthcare especially in the Indian set-up. Besides careful history taking and examination, the diagnosis and follow-up of patients of wet ARMD demands a very high standard of patient compliance. Since the patient may not be able to experience the beneficial results of an intravitreal immediately and also because the patient might probably require more than a single intravitreal injection, the responsibility of proper counselling and compliance generally falls on the shoulders of these general practitioners and family physicians.

Conclusion {#sec1-5}
==========

No significant change in endothelial cell density and central corneal thickness was found after intravitreal injection over one month of follow-up, neither in phakic nor in pseudophakic eyes.

Thus, intravitreal anti-VEGF injection appears to be safe on cornea in phakic and pseudophakic eyes in terms of corneal endothelial cell count and central corneal thickness.

Financial support and sponsorship {#sec2-2}
---------------------------------

Nil.

Conflicts of interest {#sec2-3}
---------------------

There are no conflicts of interest.
